

**DFIN CASE STUDY** 

How we helped a biopharmaceutical company with their financial reporting and IPO

Active Disclosure by **DFIN** 

ORACLE NetSuite



#### **CORPORATE SNAPSHOT**

MBX Biosciences, Inc. (NASDAQ GS: MBX) is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine and metabolic disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics.



2018

Founded in Carmel, Indiana



\$187.7M

Capital raised during their IPO in 2024



3


Potential treatments and therapies

#### **CHALLENGE**

# Automating financial reporting and getting ready for an IPO

MBX Biosciences wanted to go public, but was using Microsoft Excel, Word and PowerPoint for financial reporting and this limited controls, decreased efficiencies, and increased risk.

They decided to prepare early for life as a public company by practicing financial reporting (e.g., 10-Qs) ahead of their IPO. This meant they needed a solution that would support their new Oracle NetSuite environment and legacy Excel workbooks.



#### **SOLUTION**

## ActiveDisclosure and NetSuite for Financial Reporting and IPO

MBX Biosciences adopted ActiveDisclosure software to complement their NetSuite environment, enabling a successful IPO followed by timely quarterly and annual financial reporting and SEC filing. ActiveDisclosure ensures everything happens as a secure and collaborative online workflow, eliminating the inefficient and error-prone process of comparing and copying data from Excel workbooks to Word documents and PowerPoint presentations.



#### MODERN FINANCIAL REPORTING SOFTWARE

ActiveDisclosure helps clients maximize their productivity



MARKET-LEADING IPO EXPERIENCE

DFIN is #1 in IPOs, with 800+ filed for clients since 2017




#### **CONCIERGE SERVICE BY DFIN EXPERTS**

Our subject matter experts collaborate with client teams

NetSuite, used by more than 41,000 customers worldwide, continues providing MBX Biosciences the trusted data they use with ActiveDisclosure.

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly,



010-Cover

Josh Duncan Today - 11:16 AM

030-Balance Sheets

Stan Smith Today - 9:55 AM

040-Statements of Operations

Amy Flannery Today - 12:29 AM

Our consolidated finar as of September 30, 2 results of operations f months ended March September 30, 2020, at for 2020. Operating results ended March September 30, 2020, and September 30, 2020 necessarily indicative that may be expected

Do you want to replace this workbook?

Oneina

Updated

11 Tables

11 Tables

105 Items

105 Items

Assets

Current Assets:

Cash

Accounts received

Prepaid expens
Total current as



MBX adopted ActiveDisclosure to improve our pre-IPO readiness and post-IPO operations.

ActiveDisclosures helps us automate the production of financial reports, so we don't spend countless hours on formatting and other things that don't really matter."

### **Tyler Carner**

Senior Director & Controller MBX Biosciences





### Get in touch

#### **DFINsolutions.com**

35 West Wacker Drive Chicago, Illinois 60601 United States +1 800 823 5304

APAC: +852 2522 3803 EMEA: +44 203 047 6100 LATAM: +55 11 3031 6327